Illustration: Maura Losch/Axios
Pfizer has won the bidding war for Metsera, agreeing to pay as much as $10 billion to acquire the obesity drug developer.
Why it matters: The price is almost 40% higher than Pfizer's original $7.3 billion offer for Metsera in September.
